AstraZeneca extends virtual neuroscience reach
This article was originally published in Scrip
Executive Summary
When AstraZeneca announced in February that neuroscience R&D would be a major target of a restructuring initiative there were concerns that it might exit the whole area (www.scripintelligence.com , 2 February, 2012). To counter those fears, the company line was that it was deeply committed to neuroscience research but would take a more virtual approach that involves tapping into external expertise. As part of that strategy AstraZeneca signed its second and third deals on 12 July.